| Cerenity - Marian Of St Paul Llc | |
| 200 Earl Street, Saint Paul, Minnesota 55106 | |
| (651) 793-2100 | |
| Name | Cerenity - Marian Of St Paul Llc |
|---|---|
| Location | 200 Earl Street, Saint Paul, Minnesota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 90 |
| Occupancy Rate | 76.11% |
| Medicare ID (CCN) | 245365 |
| Legal Business Name | Cerenity-marian Of St. Paul, Llc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1386635183 |
| Organization Name | CERENITY SENIOR CARE |
| Doing Business As | CERENITY CARE CENTER - MARIAN OF SAINT PAUL |
| Address | 200 Earl St, Saint Paul, MN 55106 |
| Phone Number | 651-793-2100 |
News Archive
Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.
A person is considered a cancer survivor from the minute they are diagnosed with the disease. Tips from experts at the University of Alabama at Birmingham (UAB) can help survivors continue pre-diagnosis daily routines that may include working; one such expert, a cancer survivor herself, experienced firsthand the benefits and challenges of survivorship in the workplace.
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.
Medical Services International Inc. has announced that the interest by regulatory authorities and the company's distributors has increased substantially for its VScan Dengue Fever and Malaria test kits.
› Verified 5 days ago
| NPI Number | 1639689409 |
| Organization Name | CERENITY-MARIAN OF ST. PAUL, LLC |
| Address | 200 Earl St, Saint Paul, MN 55106 |
| Phone Number | 651-793-2100 |
News Archive
Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.
A person is considered a cancer survivor from the minute they are diagnosed with the disease. Tips from experts at the University of Alabama at Birmingham (UAB) can help survivors continue pre-diagnosis daily routines that may include working; one such expert, a cancer survivor herself, experienced firsthand the benefits and challenges of survivorship in the workplace.
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.
Medical Services International Inc. has announced that the interest by regulatory authorities and the company's distributors has increased substantially for its VScan Dengue Fever and Malaria test kits.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.
A person is considered a cancer survivor from the minute they are diagnosed with the disease. Tips from experts at the University of Alabama at Birmingham (UAB) can help survivors continue pre-diagnosis daily routines that may include working; one such expert, a cancer survivor herself, experienced firsthand the benefits and challenges of survivorship in the workplace.
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.
Medical Services International Inc. has announced that the interest by regulatory authorities and the company's distributors has increased substantially for its VScan Dengue Fever and Malaria test kits.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 9.5 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.37 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 76.34 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.77 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.59 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 5.78 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 8.55 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.72 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 8.52 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.36 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.37 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 13.74 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 8.89 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.5 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 64.33 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.6 | 82.93 |
News Archive
Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.
A person is considered a cancer survivor from the minute they are diagnosed with the disease. Tips from experts at the University of Alabama at Birmingham (UAB) can help survivors continue pre-diagnosis daily routines that may include working; one such expert, a cancer survivor herself, experienced firsthand the benefits and challenges of survivorship in the workplace.
GlaxoSmithKline plc announced today that they have signed an agreement regarding the acquisition, on a worldwide basis, of the injectable anti-thrombotic agents Fraxiparine® and Arixtra® and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Synthelabo.
The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.
Medical Services International Inc. has announced that the interest by regulatory authorities and the company's distributors has increased substantially for its VScan Dengue Fever and Malaria test kits.
› Verified 5 days ago
Highland Chateau Health Care Center Location: 2319 West Seventh Street, Saint Paul, Minnesota 55116 Phone: (651) 698-0793 | |
St Anthony Park Home Location: 2237 Commonwealth Avenue, Saint Paul, Minnesota 55108 Phone: (651) 632-3503 | |
Good Samaritan Society - Maplewood Location: 550 Roselawn Avenue East, Saint Paul, Minnesota 55117 Phone: (651) 774-9765 | |
Cerenity Care Center On Humboldt Location: 512 Humboldt Avenue, Saint Paul, Minnesota 55107 Phone: (651) 220-1700 | |
The Emeralds At St Paul Llc Location: 420 Marshall Avenue, Saint Paul, Minnesota 55102 Phone: (651) 224-2368 | |
Galtier A Villa Center Location: 445 Galtier Avenue, Saint Paul, Minnesota 55103 Phone: (651) 224-1848 |